132 related articles for article (PubMed ID: 33134565)
1. Health-related quality of life after ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: reporting the patient's perspective.
van Son M; Monninkhof E; Peters M; Lagendijk J; van der Voort van Zyp J
Clin Transl Radiat Oncol; 2020 Nov; 25():81-87. PubMed ID: 33134565
[TBL] [Abstract][Full Text] [Related]
2. MRI-Guided Ultrafocal Salvage High-Dose-Rate Brachytherapy for Localized Radiorecurrent Prostate Cancer: Updated Results of 50 Patients.
van Son MJ; Peters M; Moerland MA; Lagendijk JJW; Eppinga WSC; Shah TT; Ahmed HU; van der Voort van Zyp JRN
Int J Radiat Oncol Biol Phys; 2020 May; 107(1):126-135. PubMed ID: 32006609
[TBL] [Abstract][Full Text] [Related]
3. MRI-Guided Ultrafocal HDR Brachytherapy for Localized Prostate Cancer: Median 4-Year Results of a feasibility study.
Peters M; van Son MJ; Moerland MA; Kerkmeijer LGW; Eppinga WSC; Meijer RP; Lagendijk JJW; Shah TT; Ahmed HU; van der Voort van Zijp JRN
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1045-1053. PubMed ID: 30926575
[TBL] [Abstract][Full Text] [Related]
4. Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patients.
van Son M; Peters M; Moerland M; van de Pol S; Eppinga W; Lagendijk J; van der Voort van Zyp J
Clin Transl Radiat Oncol; 2021 Mar; 27():1-7. PubMed ID: 33364450
[TBL] [Abstract][Full Text] [Related]
5. Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.
Aluwini S; Busser WM; Alemayehu WG; Boormans JL; Kirkels WJ; Jansen PP; Praag JO; Bangma CH; Kolkman-Deurloo IK
Radiother Oncol; 2015 Nov; 117(2):252-7. PubMed ID: 26409832
[TBL] [Abstract][Full Text] [Related]
6. Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-/very high-risk prostate cancer: A dosimetric analysis of toxicity.
Sakurai T; Takamatsu S; Shibata S; Iwata K; Taka M; Gabata T; Kumano T; Makino T; Mizokami A
Jpn J Radiol; 2020 Dec; 38(12):1197-1208. PubMed ID: 32737768
[TBL] [Abstract][Full Text] [Related]
7. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer.
Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
Brachytherapy; 2018; 17(3):517-523. PubMed ID: 29496423
[TBL] [Abstract][Full Text] [Related]
8. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life.
Jo Y; Junichi H; Tomohiro F; Yoshinari I; Masato F
BJU Int; 2005 Jul; 96(1):43-7. PubMed ID: 15963118
[TBL] [Abstract][Full Text] [Related]
9. Oncological outcome, complications, lower urinary tract symptoms, and health-related quality of life after low-dose-rate salvage brachytherapy for recurrent prostate cancer following primary radiotherapy: a report of 8 cases.
Miyake M; Tanaka N; Asakawa I; Hori S; Morizawa Y; Nakai Y; Anai S; Torimoto K; Aoki K; Marugami N; Hasegawa M; Fujii T; Konishi N; Fujimoto K
J Contemp Brachytherapy; 2017 Aug; 9(4):364-372. PubMed ID: 28951757
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective Phase II study.
Nguyen PL; Chen RC; Clark JA; Cormack RA; Loffredo M; McMahon E; Nguyen AU; Suh WW; Tempany CM; D'Amico AV
Brachytherapy; 2009; 8(4):345-52. PubMed ID: 19428311
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life.
Musunuru HB; Cheung P; Vesprini D; Liu SK; Chu W; Chung HT; Morton G; Deabreu A; Davidson M; Ravi A; Helou J; Ho L; Zhang L; Loblaw A
Radiother Oncol; 2021 Aug; 161():40-46. PubMed ID: 34089752
[TBL] [Abstract][Full Text] [Related]
12. Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer.
Maenhout M; Peters M; van Vulpen M; Moerland MA; Meijer RP; van den Bosch MAAJ; Nguyen PL; Frank SJ; van der Voort van Zyp JRN
Technol Cancer Res Treat; 2017 Dec; 16(6):1194-1201. PubMed ID: 29333958
[TBL] [Abstract][Full Text] [Related]
13. The impact of acute urinary retention after iodine-125 prostate brachytherapy on health-related quality of life.
Roeloffzen EM; Hinnen KA; Battermann JJ; Monninkhof EM; van Roermund JG; van Gellekom MP; Frank SJ; van Vulpen M
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1322-8. PubMed ID: 19939578
[TBL] [Abstract][Full Text] [Related]
14. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
15. Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer.
Maenhout M; van Vulpen M; Moerland M; Peters M; Meijer R; van den Bosch M; Nguyen P; Frank S; van der Voort van Zyp J
J Contemp Brachytherapy; 2017 Apr; 9(2):161-166. PubMed ID: 28533806
[TBL] [Abstract][Full Text] [Related]
16. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
17. Health-related Quality of Life and Toxicity After Single-fraction High-dose-rate Brachytherapy With External Beam Radiotherapy for Localized and Locally Advanced Prostate Cancer.
Makino T; Nakashima K; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Kumano T; Mizokami A
Anticancer Res; 2019 Jan; 39(1):477-486. PubMed ID: 30591498
[TBL] [Abstract][Full Text] [Related]
18. Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer.
Raleigh DR; Chang AJ; Tomlin B; Cunha JA; Braunstein SE; Shinohara K; Gottschalk AR; Roach M; Hsu IC
Brachytherapy; 2015; 14(6):795-800. PubMed ID: 26198421
[TBL] [Abstract][Full Text] [Related]
19. Development and internal validation of multivariable prediction models for biochemical failure after MRI-guided focal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer.
Willigenburg T; van Son MJ; van de Pol SMG; Eppinga WSC; Lagendijk JJW; de Boer HCJ; Moerland MA; van der Voort van Zyp JRN; Peters M
Clin Transl Radiat Oncol; 2021 Sep; 30():7-14. PubMed ID: 34278009
[TBL] [Abstract][Full Text] [Related]
20. Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life.
Peters M; Maenhout M; van der Voort van Zyp JR; Moerland MA; Moman MR; Steuten LM; van Deursen MJ; van Vulpen M
Radiother Oncol; 2014 Jul; 112(1):77-82. PubMed ID: 24998704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]